乌帕替尼单药治疗与联合非生物改善病情抗风湿药治疗银屑病关节炎
汇总SELECT-PsA 1和SELECT-PsA 2两项试验中共1916例银屑病关节炎患者数据,比较乌帕替尼单药或联合非生物DMARDs治疗24周的疗效与安全性。乌帕替尼15 mg和30 mg每日一次单药与联合治疗的疗效总体一致,不良事件频率总体相似,但联合治疗时肝脏疾病和肌酸磷酸激酶升高更常见。
要点
- 共1916例患者,574例(30%)接受单药治疗,1342例(70%)接受联合治疗。
- 第12周ACR20安慰剂校正治疗效应:乌帕替尼15 mg单药33.7%(95%CI 24.4,43.1),联合34.0%(95%CI 27.9,40.1)。
- 乌帕替尼30 mg单药45.7%(95%CI 36.9,54.5),联合39.6%(95%CI 33.7,45.5)。
核心结论
- 乌帕替尼单药或联合非生物DMARDs治疗24周的疗效和安全性总体一致,支持在银屑病关节炎中使用乌帕替尼联合或不联合非生物DMARDs。
研究设计与样本
- 汇总分析SELECT-PsA 1和SELECT-PsA 2两项试验中,对一种或以上非生物DMARD应答不足或不耐受、或对一种或以上生物DMARD应答不足或不耐受的银屑病关节炎患者数据。
- 患者接受安慰剂、乌帕替尼15 mg每日一次或乌帕替尼30 mg每日一次,作为单药或联合两种或以下非生物DMARDs治疗24周。
主要发现
- 共纳入1916例患者,574例(30%)接受单药治疗,1342例(70%)接受联合治疗。
- 第12周ACR20安慰剂校正治疗效应:乌帕替尼15 mg单药33.7%(95%CI 24.4,43.1),联合治疗34.0%(95%CI 27.9,40.1)。
- 第12周ACR20安慰剂校正治疗效应:乌帕替尼30 mg单药45.7%(95%CI 36.9,54.5),联合治疗39.6%(95%CI 33.7,45.5)。
- 其他结局的治疗效应在单药与联合治疗之间一致。
- 乌帕替尼单药与联合治疗的不良事件频率总体相似,但联合治疗相比单药治疗肝脏疾病和肌酸磷酸激酶升高更常见。
关键数值与推荐
- 第12周ACR20安慰剂校正治疗效应:乌帕替尼15 mg单药33.7%(95%CI 24.4,43.1),联合治疗34.0%(95%CI 27.9,40.1)。
- 第12周ACR20安慰剂校正治疗效应:乌帕替尼30 mg单药45.7%(95%CI 36.9,54.5),联合治疗39.6%(95%CI 33.7,45.5)。
临床怎么用
- 乌帕替尼单药或联合非生物DMARDs治疗24周的疗效和安全性总体一致,支持在银屑病关节炎中使用乌帕替尼联合或不联合非生物DMARDs。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of upadacitinib (UPA), an oral Janus kinase inhibitor, as monotherapy or in combination with non-biologic DMARDs (nbDMARDs) in patients with PsA. METHODS: Pooled data were analysed from patients with prior inadequate response or intolerance to one or more nbDMARD (SELECT-PsA 1) or one or more biologic DMARD (SELECT-PsA 2) who received placebo, UPA 15 mg once daily (QD) or UPA 30 mg QD as monotherapy or in combination with two or fewer nbDMARDs for 24 weeks. Efficacy outcomes included achievement of ACR responses, Psoriasis Area and Severity Index responses, minimal disease activity and change from baseline and clinically meaningful improvement in the HAQ Disability Index. Adverse events (AEs) were summarized. RESULTS: A total of 1916 patients were included; 574 (30%) received monotherapy and 1342 (70%) received combination therapy. Placebo-subtracted treatment effects for a 20% improvement in ACR criteria at week 12 were 33.7% (95% CI 24.4, 43.1) and 34.0% (95% CI 27.9, 40.1) for UPA 15 mg QD monotherapy and combination therapy, respectively, and 45.7% (95% CI 36.9, 54.5) and 39.6% (95% CI 33.7, 45.5) for UPA 30 mg QD monotherapy and combination therapy, respectively. Treatment effects for other outcomes were consistent between monotherapy and combination therapy. AE frequency was generally similar for UPA monotherapy and combination therapy, although hepatic disorders and creatine phosphokinase elevation were more common with combination therapy vs monotherapy. CONCLUSION: The efficacy and safety of UPA were generally consistent when administered as monotherapy or in combination with nbDMARDs through 24 weeks, supporting the use of UPA with or without nbDMARDs in PsA. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov): SELECT-PsA 1 (NCT03104400), SELECT-PsA 2 (NCT03104374).
引用
- Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022. PMID: 34864911. doi:10.1093/rheumatology/keab905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。